Five Year Survival Update From KEYNOTE-010 : Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC - Herbst, Roy S (Section of Medical Oncology. Yale Comprehensive Cancer Center. Yale University School of Medicine) ; Garon, E.B. (David Geffen School of Medicine. University of California Los Angeles) ; Kim, D.W. (Seoul National University Hospital. Seoul National University College of Medicine) ; Cho, B.C. (Yonsei Cancer Center. Yonsei University College of Medicine) ; Gervais, R. (Centre François Baclesse (Caen, França)) ; Perez-Gracia, J.L. (Clínica Universidad de Navarra) ; Han, J.Y. (Center for Lung Cancer. National Cancer Center) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Forster, M.D. (UCL Cancer Institute/University College London Hospitals) ; Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ; Novello, Silvia (Department of Oncology. University of Turin. Azienda Ospedaliero Universitaria San Luigi) ; Gubens, M.A. (University of California. San Francisco) ; Boyer, M. (Chris O'Brien Lifehouse) ; Su, W.C. (National Cheng Kung University Hospital) ; Samkari, A. (Merck & Co.. Inc.) ; Jensen, E.H. (Merck & Co.. Inc.) ; Kobie, J. (Merck & Co.. Inc.) ; Piperdi, B. (Merck & Co.. Inc.) ; Baas, Pieter (The Netherlands Cancer Institute (Amsterdam, Països Baixos))